EDAP TMS（EDAP）株式概要
医療技術企業であるEDAP TMS S.A.は、アジア、フランス、米国、および国際的な非侵襲的治療用超音波およびエネルギーベースの医療機器の開発、製造、マーケティング、販売に従事している。 詳細
EDAP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$10.74
FV
60.4% 割安 内在価値ディスカウント10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
EDAP TMS S.A. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.25 |
| 52週高値 | US$5.05 |
| 52週安値 | US$1.21 |
| ベータ | -0.096 |
| 1ヶ月の変化 | 24.27% |
| 3ヶ月変化 | -9.77% |
| 1年変化 | 144.25% |
| 3年間の変化 | -57.58% |
| 5年間の変化 | -35.80% |
| IPOからの変化 | -50.00% |
最新ニュース
ナラティブの更新 • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.ナラティブの更新 • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.Recent updates
ナラティブの更新 • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.ナラティブの更新 • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.
ナラティブの更新 • Mar 29
EDAP: Longer Term Revenue Outlook Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.
ナラティブの更新 • Mar 14
EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing
Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.ナラティブの更新 • Feb 28
EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside
Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.ナラティブの更新 • Feb 14
EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside
Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).分析記事 • Feb 03
EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth
EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...ナラティブの更新 • Jan 31
EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).ナラティブの更新 • Jan 17
EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside
Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).分析記事 • Dec 20
EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Dec 13
EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...ナラティブの更新 • Aug 29
CE Mark And Global Expansion Will Elevate HIFU Adoption
Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.分析記事 • Aug 19
There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...分析記事 • Jul 03
Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 18
Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified
Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
新しいナラティブ • Apr 08
CE Mark And Global Expansion Will Elevate HIFU Adoption
New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.分析記事 • Apr 03
EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...分析記事 • Mar 15
Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...分析記事 • Dec 25
Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk
With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...分析記事 • Oct 24
Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Sep 07
Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...分析記事 • Jul 24
Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...分析記事 • Mar 22
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...分析記事 • Mar 03
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jan 19
It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...分析記事 • Aug 11
Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...分析記事 • Dec 19
Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?
Does the December share price for EDAP TMS S.A. ( NASDAQ:EDAP ) reflect what it's really worth? Today, we will estimate...分析記事 • Nov 23
EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for EDAP TMS S.A.'s ( NASDAQ:EDAP ) stock hasn't moved much. We did...Seeking Alpha • Sep 22
EDAP TMS stock falls 7% aftermarket on proposed ADS offering
EDAP TMS (NASDAQ:EDAP) stock fell ~7% postmarket after the company said it commenced a public offering of its American depositary shares, each representing one ordinary share. There can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms.Seeking Alpha • Aug 24
EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M
EDAP TMS S.A. press release (NASDAQ:EDAP): Q2 GAAP EPS of $0.06 beats by $0.09. Revenue of $14.97M (+20.3% Y/Y) beats by $1.35M. 79% growth in HIFU revenues for the first half of 2022 compared to same period in 2021 Strong cash position of $48.5 million as of June 30, 2022 Company to host Focal One Expert User Panel event in New York City on Thursday, September 29.Seeking Alpha • Aug 08
EDAP's Focal One Revenue Is Set To Accelerate
The placement of new Focal Ones got off to a good start this year and a filled-up pipeline is promising more, boosted by a big reimbursement improvement for Medicare. Reimbursement for Medicare patients' procedures almost doubled in July, significantly improving the economics for the Focal One. This should also speed up reimbursement from private payers and boost market acceptance. Most revenues still come from an exclusive distribution deal for the ExactVu with Exact Imaging, a clever move tiding the company over until reimbursement is improved. EDAP (EDAP) is a French medical device company that was known for its ESWL (extracorporeal shock wave lithotripsy) but it developed a HIFU (high-intensity focused ultrasound) robotic device, the Focal One, which is FDA approved for treating prostate cancer. HIFU works through soft tissue ablation through ultrasound, a minimally-invasive alternative for intermediate-risk prostate cancer and salvage treatment. The company got a bump in reimbursement, improving the attractiveness of the device, and there are still plenty of markets to pursue in the US and elsewhere. In the coming years, the Focal One could be approved for multiple additional indications while the company is also successfully selling the ExactVu from strategic partner Exact Imaging, which is actually responsible for most of its revenue. Growth There was, not surprisingly, a dip in the early quarters of the pandemic but apart from the last two quarters of 2021, growth has returned: Data by YCharts The most important growth vectors are: Placing more machines Increasing procedures Improving reimbursement Additional indications Placing more machines Q1 was a pretty good quarter for placing new machines, with four Focal One Robotic HIFU units sold, three of which were sold in the US at prestigious academic hospitals. Management argues that there is a growing pipeline, consisting of large academic hospitals but also increasingly community hospitals. Increasing the installed base also generates a tail of recurring revenues in the form of service contracts ($80K per year after year 1) and consumables (handpieces at $1800). They had a very successful presentation at the AUA, the American Urological Association, the largest annual gathering of neurologists worldwide where they showcased the Focal One and supported an accredited AUA course with hands-on training. Management argued they received additional interest as a result of the AUA. The company also sold nine ExactVu units (versus 5 in Q1/21), five of which were in the US, and one lithotripsy device for their legacy business (versus 6 in Q1/21). Increasing usage Management argued that the recently hired clinical sales managers had an immediate impact on usage within their existing customer base. They also engage in training programs for doctors to familiarize them with the Focal One. They didn't provide much detail on the CC about usage apart from noting that there was good usage momentum. Reimbursement The company does have a CPT (Current Procedural Terminology) code but management was disappointed when they were not bumped up to APC level 6, despite a unanimous conclusion from the advisory board. However, as expected, this all changed in July when the company finally achieved the APC level 6 code and this almost doubled the reimbursement from $4506 to $8711 (on average, there are slight variations determined by local wage levels) per procedure for Medicare patients. This not only increases the company's revenues from Medicare patients, it also furthers market adoption; from the company PR: The increase to APC level 6 has positive implications for patients beyond Medicare since many commercial payors have begun to cover focal HIFU for their members. Commercial payment and access policies are influenced by Medicare policy and reimbursement decisions. Additional indications Endometriosis BPH treatment Pancreatic cancer Liver cancer Breast cancer Endometriosis is furthest along as the company embarked on a (fairly small) P2 stage clinical trial which will end in September, with the first data expected before the end of the year. Other indications are further out. Financials From the 6-K: EDAP 6-K Results expressed in USD for Q2 will have some headwinds as the rate used in Q1 ($1.1177 euro per dollar) has come down considerably. Recurring revenues increased 17.5%, considerably less than the 44.4% rise in revenue from equipment. This isn't all that surprising as the newly sold devices do not earn any service revenue for the first year. Disaggregated revenue looks like this: EDAP 6-K It's quite remarkable that the distribution division is still by far the biggest revenue generator, this is the sales of the ExactVu, which is a device made by Exact Imaging, not EDAP. It's also the division that turns what would otherwise be an operating loss into an operating profit. That exclusive distribution deal is doing both companies wonders, no doubt about it. Margins Data by YCharts Since most of the sales come from the ExactVu, gross margins have suffered a bit since the start of 2021, but in the last two quarters, gross margins have recovered on economies of scale.株主還元
| EDAP | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 2.2% | 4.0% | -0.3% |
| 1Y | 144.3% | -18.6% | 26.7% |
業界別リターン: EDAP過去 1 年間で-18.6 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: EDAP過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| EDAP volatility | |
|---|---|
| EDAP Average Weekly Movement | 8.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: EDAP 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: EDAPの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1979 | 289 | Ryan Rhodes | focalone.com |
医療技術企業であるEDAP TMS S.A.は、アジア、フランス、米国、および国際的な非侵襲的治療用超音波およびエネルギーベースの医療機器の開発、製造、マーケティング、販売に従事している。同社は、高密度焦点式超音波（HIFU）、体外衝撃波結石破砕術（ESWL）、流通の各セグメントを通じて事業を展開している。HIFU事業では、泌尿器科関連およびその他の適応症向けの非侵襲的ロボットHIFUシステムの開発、製造、販売、流通を行っている。また、前立腺がん治療用HIFUロボットシステム「Focal One」、消耗品、リース・治療関連サービス、メンテナンスサービスも提供している。ESWL事業では、尿路結石治療用砕石器の製造・販売、砕石器の消耗品・交換部品・サービスの提供を行っている。また、電極などのスペアパーツや消耗品の販売も行っている。ディストリビューション事業では、レーザー、マイクロ超音波診断装置、その他の医療機器の販売、流通、サービス、リース、消耗品および交換部品の販売、保守サービスを行っている。同社は、ダイレクトマーケティング、販売チャネル、第三者のディストリビューターや代理店を通じて製品のマーケティングと販売を行っている。同社は、大学病院、公立病院、私立病院、診療所を顧客としている。同社はTelix Pharmaceuticals Limitedと戦略的提携を結んでおり、前立腺がんに対するPSMA PETイメージングとFocal One Robotic HIFUを組み合わせた臨床ワークフローを開発している。EDAP TMS S.A.は1979年に設立され、フランスのVaulx-en-Velinに本社を置いている。
EDAP TMS S.A. 基礎のまとめ
| EDAP 基礎統計学 | |
|---|---|
| 時価総額 | US$161.92m |
| 収益（TTM） | -US$30.88m |
| 売上高(TTM) | US$74.07m |
2.2x
P/Sレシオ-5.2x
PER（株価収益率EDAP は割高か？
公正価値と評価分析を参照収益と収入
| EDAP 損益計算書（TTM） | |
|---|---|
| 収益 | US$74.07m |
| 売上原価 | US$41.92m |
| 売上総利益 | US$32.15m |
| その他の費用 | US$63.04m |
| 収益 | -US$30.88m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.82 |
| グロス・マージン | 43.41% |
| 純利益率 | -41.70% |
| 有利子負債／自己資本比率 | 226.2% |
EDAP の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 08:10 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
EDAP TMS S.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| null null | CG Capital |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |